全球基因编辑市场规模、份额和成长分析：按类型和应用分类 - 产业预测（2023-2030）

Global Gene Editing Market Size, Share, Growth Analysis, By Type(CRISPR/Cas9, TALENS), By Application(Diagnostics, Drug discovery and development) - Industry Forecast 2023-2030

出版日期: 2023年10月16日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2021年全球基因编辑市场规模为38亿美元，从2022年的40.6亿美元成长到2030年的68.7亿美元，年复合成长率年增长率预计为6.8%。

近年来，该市场经历了显着的成长和进步，彻底改变了生物技术和基因研究部门。该市场的推动因素包括个人化医疗需求的不断增长、基因工程的进步以及研发活动投资的增加。基因编辑的治疗应用，例如遗传疾病的治疗、癌症免疫治疗和感染疾病，正在引起巨大关注并推动市场成长。此外，农业部门正在迅速采用基因编辑作物来开发提高产量、营养价值和抗病虫害能力的作物。全球市场的特征是製药公司、生技公司和研究机构等主要企业之间竞争激烈。这些公司正在积极寻求策略合作伙伴关係、併购和联盟，以加强其研究能力并扩大产品系列。由于拥有先进的医疗基础设施、强大的研究基础以及对基因组研究的大量投资，北美在全球市场占据主导地位。然而，由于中国、日本和印度等国家对精准医疗的日益关注、医疗保健成本的上升以及积极的政府配合措施，预计亚太地区将显着增长。政府的支持性配合措施、学术机构和生物技术公司之间的合作以及进入基因编辑领域的新创公司的增加也推动了该市场的发展。

全球基因编辑市场动态

全球基因编辑市场的驱动因素

个人化医疗需求不断成长

市场的主要驱动力之一是对个人化医疗不断增长的需求。基因编辑技术提供了根据个人基因组成开发客製化治疗方法的潜力。这种个体化的医疗方法有望改善治疗结果、减少副作用并提高患者的福祉。对个人化医疗的认识不断提高以及对标靶治疗的需求是基因编辑技术采用和进步的主要驱动力。

全球基因编辑市场的抑制因素

与科技相关的道德和法规问题

市场的主要抑制因素之一是与该技术相关的道德和法规挑战。遗传物质的操纵引发了复杂的伦理考虑，特别是在种系编辑和遗传改变方面。关于基因编辑的道德影响和潜在的长期后果一直存在争议。此外，管理基因编辑实践的法律规范因司法管辖区而异，并且不断发展。全面的道德准则和明确的法规途径的需求是市场成长和广泛采用的主要抑制因素。

全球基因编辑市场趋势

主要市场趋势之一是日益关注治疗应用和基因疗法开发。基因编辑技术为遗传性疾病和癌症等疾病的标靶和精准治疗开闢了新的可能性。市场正在转向治疗方法研究和临床应用，越来越多的公司和研究人员探索基因编辑作为未满足医疗需求的潜在解决方案。这一趋势反映了基因编辑在医学领域的变革潜力，以及对可直接解决疾病潜在遗传原因的创新治疗方法的追求。

本报告针对全球基因编辑市场进行研究与分析，提供市场动态与前景、細項分析、公司简介等。

Allele Biotech (US)
GE Healthcare (US)
Bio-Rad (US)
CRISPR Therapeutics (Switzerland)
Merck KGaA (Germany)
OriGene Technologies (US)
Precision Biosciences (US)
Takara Bio (Japan)
Addgene (US)
Thermo Fisher Scientific Inc. (US)
Editas Medicine (US)
Sangamo Therapeutics (US)
Lonza Group (Switzerland)
Horizon Discovery (UK)
Intellia Therapeutics (US)
Caribou Biosciences (US)
Synthego (US)
GenScript Biotech Corporation (China)
CRISPR/Cas9 Ltd. (UK)
Inscripta (US)

简介目录

Product Code: SQMIG35H2103

Global Gene Editing Market size was valued at USD 3.8 billion in 2021 and is poised to grow from USD 4.06 billion in 022 to USD 6.87 billion by 2030, growing at a CAGR of 6.8% during the forecast period (2023-2030).

The Global Gene Editing Market has experienced significant growth and advancement in recent years, revolutionizing the field of biotechnology and genetic research. Gene editing technologies, such as CRISPR-Cas9, TALENs, and zinc finger nucleases, have emerged as powerful tools for precise modification of DNA sequences in various organisms, including humans. The market is driven by the increasing demand for personalized medicine, advancements in genetic engineering, and rising investments in research and development activities. The therapeutic applications of gene editing, including the treatment of genetic disorders, cancer immunotherapy, and infectious diseases, have gained immense attention, propelling the market growth. Additionally, the agriculture sector has witnessed a surge in the adoption of gene editing techniques to develop crops with improved yield, nutritional value, and resistance to pests and diseases. Global market is characterized by intense competition among key players, including pharmaceutical companies, biotechnology firms, and research institutions. These entities are actively engaged in strategic partnerships, mergers and acquisitions, and collaborations to enhance their research capabilities and expand their product portfolios. North America dominated the global market, driven by the presence of advanced healthcare infrastructure, a strong research base, and substantial investments in genomic research. However, Asia-Pacific is expected to witness significant growth, attributed to the increasing focus on precision medicine, rising healthcare expenditure, and supportive government initiatives in countries like China, Japan, and India. The market is also fueled by supportive government initiatives, collaborations between academic institutions and biotechnology companies, and a growing number of startups entering the gene editing space.

Top-down and bottom-up approaches were used to estimate and validate the size of the global Gene Editing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gene Editing Market Segmental Analysis

The Global Gene Editing Market is segmented by type, application, and region. Based on type, the market can be segmented into CRISPR/Cas9, TALENS, ZFN, restriction enzymes and others. Based on application, the market is segmented into Diagnostics, Drug discovery and development, cell line, animal and plant genetic engineering and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Gene Editing Market Dynamics

Drivers of the Global Gene Editing Market

Increasing demand for personalized medicine

One key driver of the gene editing market is the increasing demand for personalized medicine. Gene editing technologies offer the potential to develop tailored therapies and treatments based on an individual's genetic makeup. This personalized approach to medicine holds the promise of improved treatment outcomes, reduced side effects, and enhanced patient well-being. The growing awareness of personalized medicine and the need for targeted therapies have been significant drivers in the adoption and advancement of gene editing technologies.

Restraints in the Global Gene Editing Market

Ethical and regulatory challenges associated with the technology

One key restraint of the gene editing market is the ethical and regulatory challenges associated with the technology. The manipulation of genetic material raises complex ethical considerations, particularly when it comes to germline editing and inheritable genetic changes. There are ongoing debates and discussions surrounding the moral implications and potential long-term consequences of gene editing. Additionally, regulatory frameworks governing gene editing practices vary across different jurisdictions and are continuously evolving. The need for comprehensive ethical guidelines and clear regulatory pathways poses a significant restraint to the gene editing market's growth and widespread adoption.

Market Trends of the Global Gene Editing market

One key market trend in the gene editing market is the increasing focus on therapeutic applications and the development of gene therapies. Gene editing technologies have opened up new possibilities for targeted and precise treatments of genetic disorders, cancers, and other diseases. The market is witnessing a shift towards therapeutic research and clinical applications, with a growing number of companies and researchers exploring gene editing as a potential solution for unmet medical needs. This trend reflects the transformative potential of gene editing in the field of medicine and the pursuit of innovative therapies that can directly address underlying genetic causes of diseases.

Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
- Regulatory Landscape
- Porters Analysis
Competitive rivalry
Threat of Substitute Products
Bargaining Power of Buyers
Threat of New Entrants
Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
Political Impact
Economic Impact
Social Impact
Technical Impact
Environmental Impact
Legal Impact
Global Gene Editing Market by Type
- Market Overview
- CRISPR/Cas9
- TALENS
- ZFN
- restriction enzymes and others
Global Gene Editing Market by Application
- Market Overview
- Diagnostics
- Drug discovery and development
- cell line
- animal and plant genetic engineering and others
Global Gene Editing Market Size by Region
- Market Overview
- North America
USA
Canada
- Europe
Germany
Spain
France
UK
Rest of Europe
- Asia Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
- Latin America
Brazil
Rest of Latin America
- Middle East & Africa (MEA)
GCC Countries
South Africa
Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
By Development
By Company
By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Allele Biotech (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- GE Healthcare (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Bio-Rad (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- CRISPR Therapeutics (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Merck KGaA (Germany)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- OriGene Technologies (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Precision Biosciences (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Takara Bio (Japan)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Addgene (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Thermo Fisher Scientific Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Editas Medicine (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Sangamo Therapeutics (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Lonza Group (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Horizon Discovery (UK)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Intellia Therapeutics (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Caribou Biosciences (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Synthego (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- GenScript Biotech Corporation (China)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- CRISPR/Cas9 Ltd. (UK)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Inscripta (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments